A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia
Status:
NOT_YET_RECRUITING
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicenter trial designed to evaluate treatment with romiplostim N01+ IST compared with placebo + IST in the participants with treatment-nave severe aplastic anemia.